Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 12/20 | 0.66 |
| ▸ | TNKS | O95271 | 11/20 | 0.66 |
| ▸ | PARP1 | P09874 | 10/20 | 0.66 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16366494 | 0.86 | PARP1 (0.64) | TNKS2TNKSPARP1PARP2KDM4E | |
| SCHEMBL16366317 | 0.83 | PARP1 (0.60) | TNKS2TNKSPARP1PARP2KDM4E | |
| SCHEMBL3423314 | 0.83 | TNKS (0.67) | TNKS2TNKSPARP1PARP2KDM4E | |
| SCHEMBL15857995 | 0.83 | TNKS (0.67) | TNKS2TNKSPARP1PARP2PARP14 | |
| SCHEMBL29901754 | 0.82 | PARP1 (0.52) | TNKS2TNKSPARP1PARP2KDM4E | |
| SCHEMBL28834828 | 0.82 | PARP1 (0.52) | TNKS2TNKSPARP1PARP2KDM4E | |
| SCHEMBL27913493 | 0.82 | PARP1 (0.60) | TNKS2TNKSPARP1PARP2KDM4E | |
| SCHEMBL17831899 | 0.81 | PARP1 (0.53) | TNKS2TNKSPARP1PARP2KDM4E | |
| SCHEMBL21524675 | 0.80 | TNKS (0.60) | TNKS2TNKSPARP1PARP2PARP14 | |
| SCHEMBL17298078 | 0.80 | TNKS2 (0.60) | TNKS2TNKSPARP1PARP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0897915-B1 | Quinazolinone compounds as chemotherapeutic agents | UNIV NEWCASTLE VENTURES LTD (GB) | 2003-01-22 | — | — | EP | claimed |
| EP-0897915-A1 | QUINAZOLINONE CONPOUNDS AS CHEMOTHERAPEUTIC AGENTS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1999-02-24 | — | — | EP | claimed |
| JP-H09510704-A | — | — | 1997-10-28 | — | — | JP | claimed |
| EP-0749415-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1996-12-27 | — | — | EP | claimed |
| WO-1995024379-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1995-09-14 | — | — | WO | claimed |
| WO-2017041701-A1 | NITRIC OXIDE-RELEASING PRODRUG MOLECULE | 浙江华海药业股份有限公司 | 2017-03-16 | — | — | WO | disclosed |
| WO-2014204856-A1 | FATTY ACID ANTICANCER DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| EP-0897915-B1 | Quinazolinone compounds as chemotherapeutic agents | UNIV NEWCASTLE VENTURES LTD (GB) | 2003-01-22 | — | — | EP | disclosed |
| US-5922711-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES, SHOCK OR ANALGESICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-07-13 | — | — | US | disclosed |
| EP-0897915-A1 | QUINAZOLINONE CONPOUNDS AS CHEMOTHERAPEUTIC AGENTS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1999-02-24 | — | — | EP | disclosed |
| WO-1998033802-A1 | QUINAZOLINONE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-08-06 | — | — | WO | disclosed |
| US-5708173-A | PREPARATION OF SUBSTITUTED QUINOLINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| EP-0749415-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1996-12-27 | — | — | EP | disclosed |
| US-5563162-A | CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| WO-1995024379-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1995-09-14 | — | — | WO | disclosed |
| EP-0622361-A1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | ACHE, PSEN1, PSEN2 | TNKS2 2694/4885TNKS 2808/4885PARP1 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.